
Merck Pays $10 Billion for Verona in Effort to Diversify Beyond Keytruda
Merck & Co. unveiled a $10 billion takeover of U.K.-based Verona Pharma as a strategic move to diversify its respiratory medicine pipeline and counterbalance its heavy dependence on the blockbuster cancer medicine Keytruda. The deal points to the U.S. pharma giant's relentless effort to restructure